Pink Sheet
>>Market Access
>>Pricing Debate

340B Reforms: Oversight Hearing Suggests Slow, Piecemeal Approach

19 Jul 2017

• By Michael McCaughan

There appears to be bipartisan interest in beefing up HRSA’s ability to oversee the 340B program – but the next step is likely to be more hearings and fact-finding, not immediate legislative changes.

Silhouette of a doctor walking in a hurry in the hospital corridor.

The House Energy & Commerce/Oversight Subcommittee’s July 18 hearing on the 340B drug discount program suggests that there is serious, bipartisan interest in updating the 1992 legislation that created the program – but that the process will move forward slowly and carefully.

Subcommittee Chairman Tim Murphy (R-Pa.) and Ranking Democrat Diana DeGette (D-Colo.) gave every indication of intending to continue their review...